Related Experiment Video
Updated: Jul 15, 2026

Safety Precautions and Operating Procedures in an (A)BSL-4 Laboratory: 1. Biosafety Level 4 Suit Laboratory Suite Entry and Exit Procedures
Published on: October 3, 2016
Regulating biorisks: developing a coherent policy logic (part II)
1BIOS Centre, London School of Economics and Political Science, London, UK. F.Lentzos@lse.ac.uk
Abstract:
This is the second of two articles that empirically details the working practices of regulators charged with overseeing biological research. The first article considered how regulators from the Biological Agents Unit of the UK Health and Safety Executive went about implementing the British legislation controlling work with biological agents and genetically modified organisms prior to the terrorist attacks of 11 September 2001 and the ensuing anthrax letters in the U.S. This second article continues the investigation of the Biological Agents Unit's working practices by considering how its activities have changed and adapted to the new, post-9/11 policy and regulatory environment. The main argument put forward in the articles is that an understanding of the implementation processes--that is, the strategies adopted by regulatory agencies and the styles employed by agency regulators in their interactions with those regulated--is critical to developing a coherent policy logic for the emerging regulatory regime around biorisks.
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Drug Control Governance: Regulatory Bodies and Their Impact
Hazard Analysis and Critical Control Points (HACCP)
Drug Regulation
Global Regulatory Systems
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

